IP Verse

Cellect competitive analysis

Latest publications and patents of Cellect New

Explore the latest publications and patents granted to Cellect, showcasing their recent innovations and technological advancements.

Last updated on: Sep 24, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Cellect

EP4368705
Jan 1, 2025Method For Generating T-Cells Compatible For Allogenic TransplantationGranted And Under Opposition
EP2997141
Oct 12, 2022Cd19 Specific Chimeric Antigen Receptor And Uses ThereofGranted And Under Opposition
EP3116902
Jan 1, 2020Method For Generating T-Cells Compatible For Allogenic TransplantationRevoked
EP3189073
Dec 25, 2019Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer ImmunotherapyGranted And Under Opposition
EP3126390
Oct 16, 2019Cd33 Specific Chimeric Antigen Receptors For Cancer ImmunotherapyGranted And Under Opposition
EP3008186
Nov 28, 2018Methods For Non-Transgenic Genome Editing In PlantsGranted And Under Opposition
EP3105317
Sep 19, 2018Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological CellsOpposition Rejected
EP3004349
Mar 28, 2018A Method For Producing Precise Dna Cleavage Using Cas9 Nickase ActivityGranted And Under Opposition
EP3004337
Aug 2, 2017Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease SystemOpposition Rejected

Latest patents of Cellect opposed by its competitors

Explore Cellect's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4368705
Jan 1, 2025Method For Generating T-Cells Compatible For Allogenic Transplantation1
EP2997141
Oct 12, 2022Cd19 Specific Chimeric Antigen Receptor And Uses Thereof1
EP3116902
Jan 1, 2020Method For Generating T-Cells Compatible For Allogenic Transplantation4
EP3189073
Dec 25, 2019Trophoblast Glycoprotein (5T4, Tpbg) Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP3126390
Oct 16, 2019Cd33 Specific Chimeric Antigen Receptors For Cancer Immunotherapy1
EP3008186
Nov 28, 2018Methods For Non-Transgenic Genome Editing In Plants4
EP3105317
Sep 19, 2018Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells2
EP3004349
Mar 28, 2018A Method For Producing Precise Dna Cleavage Using Cas9 Nickase Activity1
EP3004337
Aug 2, 2017Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease System1

Latest PTAB cases involving Cellect

Discover the latest PTAB cases involving Cellect, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 30, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Cellect

IPR2020-00572Feb 19, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00571Feb 19, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00569Feb 19, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00568Feb 19, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00567Feb 18, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00566Feb 18, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00565Feb 18, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00564Feb 17, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00563Feb 17, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied
IPR2020-00562Feb 17, 2020SAMSUNG ELECTRONICSCELLECTInstitution Denied

Peer Comparison New

IP litigation analysis comparing Cellect with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
CELLECTIS - 16 - - Non-Active
BARKER BRETTELL5 - - - Highly Aggressive
CENTURY THERAPEUTICS2 - - - Highly Aggressive
JAMES POOLE151 - - - Highly Aggressive